The Anti-Tumor Effects of Carboplatin, Progesterone, and Calcitriol in Endometrial Cancer Cells

Year 2022, Volume: 8 Issue: 1, 48 - 66, 30.04.2022

Ezgi Özdemir , Özgür Deniz Turan , Çiğdem Yenisey

Abstract

Aim: Platinum analogs and progesterone are used in the treatment of endometrial cancer. With calcitriol having anti-carcinogenic effects on many cancers, its effects on endometrial cancer are not clearly known. Therefore, we planned our study to compare the anti-tumor effects of carboplatin, progesterone, and calcitriol in endometrial cancer cell culture.
Material and Methods: Ishikawa cells were used in our study as endometrial cancer cell culture. A control group in which no medication was used, was compared with the study groups that received carboplatin, progesterone, and calcitriol. Anti-tumor effects of carboplatin, progesterone, and calcitriol were calculated by using the apoptosis and viability rates for each agent and its combinations (carboplatin + progesterone, carboplatin + calcitriol).
Results: The viability rates of all three agents were found significantly lower when they were compared alone or in combination with the control group (p <0.001). When cell viability with carboplatin + progesterone combination was compared with carboplatin alone, no significant difference was observed (p> 0.05). However, when the cell viability levels of the carboplatin + calcitriol combination were compared with the carboplatin used alone, it was observed that calcitriol triggered the anti-tumor effects of carboplatin and increased cell death (p = 0.001).
Conclusion: It was observed that carboplatin, progesterone, and calcitriol dose and time-dependently increased their inhibitory effects on tumor cells. Besides, when calcitriol was used combined with carboplatin, it enhanced its lethal effects on cells. The use of carboplatin and calcitriol combined in endometrial cancer may be an option in the treatment of this cancer type with high mortality. Further studies are needed to support this opinion.

Keywords

Endometrial Cancer, Carboplatin, Progesterone, Calcitriol

References

• 1. Cancer statistics. Siegel, R, et al., et al. 2014, CA Cancer J Clin, pp. 64(1):9-29.
• 2. Abnormal uterine bleeding and prognosis of endometrial cancer. Kimura, T, et al., et al. 2004, The International Journal of Gynecology & Obstetrics , pp. 85(2):p.145-150.
• 3. The presence of postmenopausal bleeding as prognostic parameter in patients with endometrial cancer: a retrospective multi-center study. Seebacher, Veronika , et al., et al. 460, s.l. : BMC Cancer, 2009.
• 4. Epidemiology of endometrial cancer. Purdie , D and Green, A. 153:341-54, s.l. : Best Pract Res Clin Obstet Gynaecol, 2001.
• 5. Pravastatin attenuates carboplatin-induced nephrotoxicity in rodents via peroxisome proliferator-activated receptoralpha-regulated heme oxygenase-1. Chen, H, Chen , T and Lin, H. 78(1):36-45, s.l. : Mol Pharmacol, 2010.
• 6. Role of Progesterone in Endometrial Cancer. Julie , KJ and Eloise, CD. s.l. : Semin Reprod Med, 2010, Vols. 28:81–90.
• 7. Sparing fertility in young patients with endometrial cancer. Chiva , L, et al., et al. s.l. : Gynecol Oncol, 2008, Vols. 111:S101–4.
• 8. DNA damage induced by cis- and carboplatin as indicator for in vitro sensitivity of ovarian carcinoma cells. Unger, F, et al., et al. 9:359, s.l. : BMC Cancer, 2009.
• 9. Vitamin D and Endometrium: A Systematic Review of a Neglected Area of Research. Chiara Cermisoni, G, et al., et al. 19(8): 2320, s.l. : Int J Mol Sci, 2018.
• 10. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Colombo, N, et al., et al. 6:33-8, s.l. : Ann Oncol, 2011.
• 11. Comparative Evaluation of Cisplatin and Carboplatin Sensitivity in Endometrial Adenocarcinoma Cell Lines. Rantanen , V, et al., et al. 69(3): 482–6, s.l. : Br J Cancer, 1994.
• 12. Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Endometrial Cancer Cells In Vitro. Kuittinen , T, et al., et al. 37(12):6575-81, s.l. : Anticancer Res, 2017.
• 13. Progesterone and Calcitriol Attenuate Inflammatory Cytokines CXCL1 and CXCL2 in Ovarian and Endometrial Cancer Cells. Kavandi, L, et al., et al. 113:3143–52, s.l. : J Cell Biochem, 2012.
• 14. Progesterone and 1,25-Dihydroxyvitamin D3 Inhibit Endometrial Cancer Cell Growth by Upregulating Semaphorin 3B and Semaphorin 3F. Nguyen, H, et al., et al. 9(11); 1–14, s.l. : Mol Cancer Res, 2011.